Thelansis

Obstructive sleep apnea (OSA) is a common sleep disorder affecting millions of people worldwide. It is characterized by repetitive pauses in breathing during sleep. These pauses can last several seconds and occur hundreds of times in a single night. OSA can cause various symptoms, including loud snoring, daytime sleepiness, morning headaches, irritability, and problems with memory. It can also increase the risk of developing other serious health problems like heart disease, stroke, and diabetes. Despite the high prevalence of OSA, many people are unaware of the condition. A recent study found that the awareness of OSA is only 21.5% in developed nations. Additionally, many people with OSA do not realize they have the condition and do not seek treatment.   Thelansis’s “Obstructive Sleep Apnea (OSA) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, compe...

 Obstructive sleep apnea (OSA) is characterized by repetitive apnea during sleep. The main nocturnal symptoms of OSAS are loud and irregular snoring, breathing pauses, restless sleep, and daytime sleepiness. Other symptoms include morning headache, irritability, problems with memory, nocturnal polyuria, and excessive sweating at night. From the study, it’s evident that the awareness of OSA was as high as 21.5% in developed nations, and nearly ~1 billion adults aged 30–69 years worldwide may have obstructive sleep apnoea. ·        Around 39% of patients have moderate to severe Obstructive sleep apnea (OSA), and ~47% of patient needs treatment or hospital visit. Thelansis’s “Obstructive Sleep Apnea (OSA) Market Outlook, Epidemiology, Competitive Landscape , and Market Forecast Report – 2021 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, pat...

  Obstructive sleep apnea (OSA) is characterised by repetitive apnea during sleep. The main nocturnal symptoms of OSAS are loud and irregular snoring, breathing pauses, restless sleep, and daytime sleepiness. Other symptoms include morning headache, irritability, memory problems, nocturnal polyuria, and excessive sweating at night. The study shows that the awareness of OSA was as high as 21.5% in developed nations, and nearly ~1 billion adults aged 30–69 years worldwide may have obstructive sleep apnoea. Around 39% of patients have moderate to severe Obstructive sleep apnea (OSA), and ~47% of patients need treatment or hospital visits. The competitive landscape of Obstructive Sleep Apnea (OSA) includes country-specific approved and pipeline therapies. Any asset/product-specific designation or review and Accelerated Approval are tracked and supplemented with analyst commentary. KOLs insights of Obstructive Sleep Apnea (OSA) across 8 MM market from the centre of Excellence/ Publ...